NCT00906035 - The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2010

Conditions

Peripheral Arterial Disease

Interventions

DRUG

Dipyridamole 200mg and Aspirin 25mg bid:

All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

DRUG

Dipyridamole 200 mg bid

All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

DRUG

Aspirin 25 mg bid

All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

Trial Locations (3)

19104

Presbyterian Hospital, 51 N. 39th St., Philadelphia

Translational Research Ctr.,3400 Civic Center Blvd, Building 421, 10th floor, Room 421, Philadelphia

University of Pennsylvania, Philadelphia